de VanEck Associates Vertex Pharmaceuticals VRTX Historial de posiciones en acciones
Compró
Mantenido
Vendió
| Trimestre | Valor de mercado | Estado | Núm. de acciones |
Cambio en la participación | Valor operado | Peso en el portafolio | Posición de la cartera | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | USD 71.5 M | Vender |
143,881
-2,235
| -2% | -USD 991 k | 0.04% | 221 |
|
|
2026
Q1 | USD 65.2 M | Vender |
146,116
-3,335
| -2% | -USD 1.56 M | 0.05% | 234 |
|
|
2025
Q4 | USD 67.8 M | Comprar |
149,451
+395
| +0.3% | +USD 170 k | 0.06% | 204 |
|
|
2025
Q3 | USD 58.4 M | Comprar |
149,056
+8,355
| +6% | +USD 3.49 M | 0.05% | 203 |
|
|
2025
Q2 | USD 62.6 M | Vender |
140,701
-990
| -0.7% | -USD 456 k | 0.07% | 182 |
|
|
2025
Q1 | USD 68.7 M | Vender |
141,691
-17,578
| -11% | -USD 8.19 M | 0.09% | 156 |
|
|
2024
Q4 | USD 64.1 M | Comprar |
159,269
+7,841
| +5% | +USD 3.63 M | 0.08% | 159 |
|
|
2024
Q3 | USD 71.2 M | Comprar |
151,428
+6,588
| +5% | +USD 3.16 M | 0.09% | 144 |
|
|
2024
Q2 | USD 67.9 M | Vender |
144,840
-7,058
| -5% | -USD 3.06 M | 0.1% | 148 |
|
|
2024
Q1 | USD 63.5 M | Vender |
151,898
-22,329
| -13% | -USD 9.44 M | 0.1% | 144 |
|
|
2023
Q4 | USD 70.9 M | Comprar |
174,227
+20,466
| +13% | +USD 7.56 M | 0.13% | 126 |
|
|
2023
Q3 | USD 53.5 M | Vender |
153,761
-10,368
| -6% | -USD 3.63 M | 0.12% | 144 |
|
|
2023
Q2 | USD 57.8 M | Vender |
164,129
-11,535
| -7% | -USD 3.89 M | 0.13% | 139 |
|
|
2023
Q1 | USD 55.3 M | Comprar |
175,664
+12,001
| +7% | +USD 3.6 M | 0.13% | 140 |
|
|
2022
Q4 | USD 47.3 M | Vender |
163,663
-11,507
| -7% | -USD 3.51 M | 0.12% | 153 |
|
|
2022
Q3 | USD 50.7 M | Comprar |
175,170
+14,239
| +9% | +USD 4.1 M | 0.15% | 139 |
|
|
2022
Q2 | USD 45.3 M | Comprar |
160,931
+16,201
| +11% | +USD 4.34 M | 0.12% | 161 |
|
|
2022
Q1 | USD 37.8 M | Vender |
144,730
-14,792
| -9% | -USD 3.51 M | 0.08% | 194 |
|
|
2021
Q4 | USD 35 M | Vender |
159,522
-19,656
| -11% | -USD 3.82 M | 0.08% | 194 |
|
|
2021
Q3 | USD 32.5 M | Comprar |
179,178
+37,885
| +27% | +USD 7.4 M | 0.08% | 202 |
|
|
2021
Q2 | USD 28.5 M | Comprar |
141,293
+20,403
| +17% | +USD 4.27 M | 0.07% | 217 |
|
|
2021
Q1 | USD 26 M | Comprar |
120,890
+8,816
| +8% | +USD 1.94 M | 0.07% | 204 |
|
|
2020
Q4 | USD 26.5 M | Comprar |
112,074
+11,937
| +12% | +USD 2.74 M | 0.08% | 186 |
|
|
2020
Q3 | USD 27.2 M | Vender |
100,137
-5,440
| -5% | -USD 1.5 M | 0.09% | 149 |
|
|
2020
Q2 | USD 30.6 M | Comprar |
105,577
+30,833
| +41% | +USD 8.36 M | 0.11% | 143 |
|
|
2020
Q1 | USD 17.8 M | Vender |
74,744
-15,326
| -17% | -USD 3.52 M | 0.09% | 153 |
|
|
2019
Q4 | USD 19.7 M | Vender |
90,070
-14,013
| -13% | -USD 2.84 M | 0.08% | 176 |
|
|
2019
Q3 | USD 17.6 M | Vender |
104,083
-6,728
| -6% | -USD 1.19 M | 0.08% | 171 |
|
|
2019
Q2 | USD 20.3 M | Vender |
110,811
-5,617
| -5% | -USD 982 k | 0.1% | 167 |
|
|
2019
Q1 | USD 21.4 M | Comprar |
116,428
+1,174
| +1% | +USD 217 k | 0.11% | 155 |
|
|
2018
Q4 | USD 19.1 M | Vender |
115,254
-14,048
| -11% | -USD 2.43 M | 0.1% | 169 |
|
|
2018
Q3 | USD 24.9 M | Vender |
129,302
-10,602
| -8% | -USD 1.89 M | 0.12% | 153 |
|
|
2018
Q2 | USD 23.8 M | Comprar |
139,904
+6,799
| +5% | +USD 1.05 M | 0.11% | 155 |
|
|
2018
Q1 | USD 21.7 M | Vender |
133,105
-56,839
| -30% | -USD 9.28 M | 0.11% | 157 |
|
|
2017
Q4 | USD 28.5 M | Vender |
189,944
-17,388
| -8% | -USD 2.57 M | 0.14% | 151 |
|
|
2017
Q3 | USD 31.5 M | Vender |
207,332
-24,813
| -11% | -USD 3.73 M | 0.16% | 133 |
|
|
2017
Q2 | USD 29.9 M | Vender |
232,145
-104,719
| -31% | -USD 12.6 M | 0.16% | 117 |
|
|
2017
Q1 | USD 36.8 M | Vender |
336,864
-3,722
| -1% | -USD 328 k | 0.16% | 107 |
|
|
2016
Q4 | USD 25.1 M | Comprar |
340,586
+58,750
| +21% | +USD 4.78 M | 0.13% | 119 |
|
|
2016
Q3 | USD 24.6 M | Comprar |
281,836
+25,434
| +10% | +USD 2.4 M | 0.11% | 117 |
|
|
2016
Q2 | USD 22.1 M | Vender |
256,402
-14,403
| -5% | -USD 1.24 M | 0.11% | 107 |
|
|
2016
Q1 | USD 21.5 M | Comprar |
270,805
+18,851
| +7% | +USD 1.71 M | 0.15% | 120 |
|
|
2015
Q4 | USD 31.7 M | Comprar |
251,954
+803
| +0.3% | +USD 96.9 k | 0.25% | 101 |
|
|
2015
Q3 | USD 26.2 M | Vender |
251,151
-31,626
| -11% | -USD 4.06 M | 0.2% | 111 |
|
|
2015
Q2 | USD 34.9 M | Comprar |
282,777
+1,315
| +0.5% | +USD 166 k | 0.21% | 119 |
|
|
2015
Q1 | USD 33.2 M | Comprar |
281,462
+34,779
| +14% | +USD 4.17 M | 0.19% | 115 |
|
|
2014
Q4 | USD 29.3 M | Vender |
246,683
-11,988
| -5% | -USD 1.35 M | 0.18% | 116 |
|
|
2014
Q3 | USD 29.1 M | Vender |
258,671
-42,648
| -14% | -USD 4.06 M | 0.15% | 126 |
|
|
2014
Q2 | USD 28.5 M | Vender |
301,319
-59,317
| -16% | -USD 4.16 M | 0.13% | 128 |
|
|
2014
Q1 | USD 25.5 M | Comprar |
360,636
+47,283
| +15% | +USD 3.74 M | 0.13% | 128 |
|
|
2013
Q4 | USD 23.3 M | Comprar |
313,353
+70,918
| +29% | +USD 4.94 M | 0.12% | 129 |
|
|
2013
Q3 | USD 18.4 M | Comprar |
242,435
+62,629
| +35% | +USD 4.98 M | 0.09% | 122 |
|
|
2013
Q2 | USD 14.4 M | Comprar |
+179,806
| Nuevas | +USD 13.2 M | 0.08% | 122 |
|
Otros fondos que tienen VRTX en su cartera
Posición de VanEck Associates en VRTX: resumen de T2 2026
VanEck Associates redujo su participación en Vertex Pharmaceuticals (VRTX) en 1.5% durante T2 2026, al vender acciones por un valor estimado de USD 991 k, y conservó 143,881 acciones valuadas en USD 71.5 M. La posición representa 0.04% de la cartera y ocupa el puesto #221.
VanEck Associates reportó por primera vez una posición en VRTX en T2 2013 y la ha mantenido durante 53 trimestres desde entonces. Al cierre de T2 2026, 1,766 fondos que sigue Wall St. Rank mantienen una posición en VRTX.
- Al cierre de T2 2026, VanEck Associates tenía 143,881 acciones de Vertex Pharmaceuticals con un valor de USD 71.5 M.
- VanEck Associates vendió 2,235 acciones de Vertex Pharmaceuticals en T2 2026, por un valor estimado de USD 991 k.
- Vertex Pharmaceuticals representó 0.04% de la cartera de VanEck Associates en T2 2026 y fue su posición número 221.
- VanEck Associates reportó por primera vez una posición en Vertex Pharmaceuticals en T2 2013 y la ha mantenido durante 53 trimestres desde entonces.
- Al cierre de T2 2026, 1,766 fondos que sigue Wall St. Rank tenían Vertex Pharmaceuticals en cartera.
Según el Informe 13F de VanEck Associates correspondiente a T2 2026, presentado el 14 ago 2026.